Asset Details
Do you wish to reserve the book?
Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
Do you wish to request the book?
Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
2024
Overview
Background
This analysis evaluated aqueous humour (AH) interleukin (IL)-6 concentrations and the association between AH IL-6 and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) receiving anti–vascular endothelial growth factor (VEGF) monotherapy.
Methods
Post hoc analysis of the multicentre, double-masked, randomised HARBOR (NCT00891735) and READ-3 (NCT01077401) trials. HARBOR enrolled treatment-naïve nAMD patients. READ-3 enrolled treatment-naïve/previously treated DMO patients. HARBOR patients received ranibizumab 0.5 or 2.0 mg monthly or as needed; AH samples were collected at month 2, after two previous intravitreal injections. READ-3 patients received ranibizumab 0.5 or 2.0 mg as needed; AH samples were collected at baseline and months 3, 6, 9, and 12. Main outcome measure: association between AH IL-6 concentrations and month 24 best-corrected visual acuity (BCVA).
Results
In both trials (HARBOR,
N
= 36; READ-3,
N
= 137), patients with higher AH IL-6 concentrations had worse visual outcomes. HARBOR patients with low AH IL-6 concentrations at month 2 had a mean (95% CI) BCVA change at month 24 of +2.9 (−2.6, 8.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of −9.0 (−22.7, 4.7) letters. READ-3 patients with low AH concentrations at baseline had a mean (95% CI) BCVA change at month 12 of +9.3 (7.4, 11.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of +5.6 (2.2, 9.1) letters.
Conclusions
Higher IL-6 AH concentrations may predict suboptimal visual responses to anti–VEGF monotherapy in patients with nAMD/DMO.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 692/699
/ Acuity
/ Age
/ Aged
/ Angiogenesis Inhibitors - administration & dosage
/ Angiogenesis Inhibitors - therapeutic use
/ Diabetic Retinopathy - drug therapy
/ Diabetic Retinopathy - metabolism
/ Diabetic Retinopathy - physiopathology
/ Edema
/ Female
/ Humans
/ Macular Edema - drug therapy
/ Male
/ Medicine
/ Pharmaceutical Sciences/Technology
/ Ranibizumab - administration & dosage
/ Ranibizumab - therapeutic use
/ Surgery
/ Vascular endothelial growth factor
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
/ Vascular Endothelial Growth Factor A - metabolism
/ Wet Macular Degeneration - drug therapy
